ScreenerHero

PRAXPraxis Precision Medicines, Inc.

NAS · US · Healthcare · Biotechnology · praxismedicines.com
375.94USD+3.12%Mkt Cap: 10.50B $P/E: —

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance i…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap10.50B $
Enterprise Value9.42B $
Revenue (TTM)—
Gross Profit-290.71M $
Net Income (TTM)-303.27M $
Revenue/Share—
Last Price375.94 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees168
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-39.23
PEG—
EV/EBITDA-24.92
EV/Revenue—
P/S—
P/B7.59
EPS (TTM)-12.23
EPS (Forward)-9.29
52W Range
37.1995% of range392.70
52W High392.70 USD
52W Low37.19 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-34.54%
ROA-32.33%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-249.07M $
CapEx (TTM)56.00K $
FCF Margin—
FCF Yield-1.90%
Net Debt-757.46M $
Net Debt/EBITDA2.00
Balance Sheet
Debt/Equity0.00
Current Ratio15.73
Quick Ratio15.46
Book Value/Sh48.04 USD
Cash/Share27.17 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:15
Split DateNov 29, 2023
Analyst Consensus
Rating1.5 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)638.68 USD
Upside (mean)+69.9%
Target Range188.00 USD – 1201.00 USD
$188.00+69.9% to mean$1201.00
# Analysts19
Ownership
Shares Out.27.92M
Float24.08M
Insiders0.28%
Institutions123.10%
Short Interest
Short Ratio9.6d
Short % Float13.15%
Short % Out.13.12%
Shares Short3.66M
Short (prev mo.)3.99M
Technical
SMA 50321.20 (+17.0%)
SMA 200297.81 (+26.2%)
Beta2.78
S&P 52W Chg18.16%
Avg Vol (30d)377.72K
Avg Vol (10d)417.28K
Technical Indicators
RSI (14)60.3
MACD17.0302
MACD Signal14.5230
MACD Hist.+2.5072
BB Upper410.90 USD
BB Middle343.58 USD
BB Lower276.26 USD
BB Width39.19%
ATR (14)21.45 USD
Vol Ratio (20d)0.96x